These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 9712735

  • 21. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP, Burns KL, Rosenberg AE, Louis DN.
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [Abstract] [Full Text] [Related]

  • 22. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
    Gao L, Liu L, van Meyel D, Cairncross G, Forsyth P, Kimmel D, Jenkins RB, Lassam NJ, Hogg D.
    Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
    [Abstract] [Full Text] [Related]

  • 23. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
    Kubo A, Nakagawa K, Varma RK, Conrad NK, Cheng JQ, Lee WC, Testa JR, Johnson BE, Kaye FJ, Kelley MJ.
    Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
    [Abstract] [Full Text] [Related]

  • 24. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.
    Yarbrough WG, Buckmire RA, Bessho M, Liu ET.
    J Natl Cancer Inst; 1999 Sep 15; 91(18):1569-74. PubMed ID: 10491434
    [Abstract] [Full Text] [Related]

  • 25. Docking-dependent regulation of the Rb tumor suppressor protein by Cdk4.
    Wallace M, Ball KL.
    Mol Cell Biol; 2004 Jun 15; 24(12):5606-19. PubMed ID: 15169919
    [Abstract] [Full Text] [Related]

  • 26. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparotto D, D'Orazi C, Boiocchi M.
    Int J Cancer; 1997 Feb 20; 74(1):26-30. PubMed ID: 9036865
    [Abstract] [Full Text] [Related]

  • 27. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
    Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, El-Naggar A, Yu D.
    Clin Cancer Res; 1998 Apr 20; 4(4):1065-70. PubMed ID: 9563903
    [Abstract] [Full Text] [Related]

  • 28. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
    Sonoda Y, Yoshimoto T, Sekiya T.
    Oncogene; 1995 Nov 16; 11(10):2145-9. PubMed ID: 7478535
    [Abstract] [Full Text] [Related]

  • 29. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4.
    Li J, Joo SH, Tsai MD.
    Biochemistry; 2003 Nov 25; 42(46):13476-83. PubMed ID: 14621993
    [Abstract] [Full Text] [Related]

  • 30. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
    Calbó J, Serna C, Garriga J, Graña X, Mazo A.
    Cell Death Differ; 2004 Oct 25; 11(10):1055-65. PubMed ID: 15309028
    [Abstract] [Full Text] [Related]

  • 31. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
    Semczuk A, Miturski R, Skomra D, Jakowicki JA.
    Arch Gynecol Obstet; 2004 Jan 25; 269(2):104-10. PubMed ID: 14648178
    [Abstract] [Full Text] [Related]

  • 32. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
    Fuxe J, Akusjärvi G, Goike HM, Roos G, Collins VP, Pettersson RF.
    Cell Growth Differ; 2000 Jul 25; 11(7):373-84. PubMed ID: 10939591
    [Abstract] [Full Text] [Related]

  • 33. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
    Serrano M, Hannon GJ, Beach D.
    Nature; 1993 Dec 16; 366(6456):704-7. PubMed ID: 8259215
    [Abstract] [Full Text] [Related]

  • 34. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
    Dirks PB, Rutka JT, Hubbard SL, Mondal S, Hamel PA.
    Oncogene; 1998 Aug 20; 17(7):867-76. PubMed ID: 9780003
    [Abstract] [Full Text] [Related]

  • 35. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
    McKenzie HA, Fung C, Becker TM, Irvine M, Mann GJ, Kefford RF, Rizos H.
    Hum Mutat; 2010 Jun 20; 31(6):692-701. PubMed ID: 20340136
    [Abstract] [Full Text] [Related]

  • 36. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T, Henke C, Korabiowska M, Schlott T, Zimmerman B, Kunze E.
    Anticancer Res; 2004 Jun 20; 24(2B):1011-23. PubMed ID: 15161057
    [Abstract] [Full Text] [Related]

  • 37. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
    Sandhu C, Peehl DM, Slingerland J.
    Cancer Res; 2000 May 15; 60(10):2616-22. PubMed ID: 10825132
    [Abstract] [Full Text] [Related]

  • 38. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R, Shiohara M, Koeffler HP, Fagin JA.
    Cancer; 1998 Nov 15; 83(10):2185-93. PubMed ID: 9827724
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
    Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland RL.
    Int J Cancer; 1996 Apr 10; 66(2):249-54. PubMed ID: 8603820
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.